Shaping better health
REMEDY : BNSSG referral pathways & Joint Formulary

BNSSG Paediatric Joint Formulary

BNSSG Paediatric Recent Formulary Decisions

Checked: not set yet by Next Review: not set yet

4.4   Atomoxetine (Strattera®) (TLS Amber) SCP click here

  • ADHD in childhood

 

2.5.5 Captopril (tablets) (TLS Amber) SCP click here

  • Paediatric cardiology 

 

2.2.4 Chlorothiazide (TLS Red)

  • Neonates (unlicensed)

 

3.2 Flutiform® (fluticasone & Formoterol) (TLS Green)

  • in adolescents aged 12 and above

 

4.4 Methylphenidate - all formulations (TLS Amber) SCP click here

  • ADHD children & adolescents

 

Decision 29th May 2012 

Diamorphine nasal (Ayendi®) Paediatric analgesia (TLS Red)

  • Approved for the use in emergency departments and MIU

 

June 2013

14.5  Rotavirus live vaccine (Rotarix®) (TLS Green)

  • Active immunisation of infants from the age of 6 weeks for prevention of gastroenteritis due to rotavirus infection
  • Please see DoH/PHE FAQs for further information

 

October 2013

4.4 Lisdexamfetamine (TLS Red)

  • An alternative treatment for Attention deficit hyperactivity disorder when there has been an inadequate response to methylphenidate.

  

December 2013

13.8.1 Dundee Sunscreen (TLS Red)

  • When other reflectant sunscreens have failed

 

January 2014

1.Misc  Infloran (Bifidobacterium infantis, Lactobacillus acidophilus) (TLS Red)

  • For use in preterm infants less than 32 weeks gestation or < 1.5kg in weight until they reach at least 34 weeks corrected gestational age and have tolerated at least 2 weeks of enteral feeds.

 

September 2016

Clonidine Patches (TLS Red)

  • For patients with secondary dystonia and dyskinesia, according to UHBristol treatment pathway for Medical management of dystonia.

 

October 2016

Esomeprazole granules (TLS Red)

  • For patients with NG tubes or second line in children with swallowing difficulties.